Leukocyte migration inhibition responses in canine lymphosarcoma.
The leukocyte migration inhibition (LMI) responses of 16 cases of canine lymphosarcoma were assessed at several stages of a combined chemotherapy immunotherapy regime. Pooled allogeneic lymphosarcoma cells used in treatment together with other allogeneic lymphosarcoma cells and autochthonous tumour cells were employed as antigens. Positive inhibitions were detected at all stages of treatment when medium controls were used but were not detected in five normal dogs with the same control. There was no association between relapse and remission and LMI response. When a normal lymph-node cell control was used only four dogs produced positive responses, all of which occurred after allogeneic cell administration. These positive responses could not be completely accounted for by sensitization to histocompatibility antigens but as they occurred both in remission and in relapse, including very advanced cases necessitating euthanasia, they were of no value in determining prognoses.
D000818:Animals; D000951:Antigens, Neoplasm; D001500:BCG Vaccine / Q000627:therapeutic use; D002464:Cell Migration Inhibition; D003520:Cyclophosphamide / Q000627:therapeutic use; D004285:Dogs; D007114:Immunization; D007962:Leukocytes / Q000276:immunology*; D008198:Lymph Nodes / Q000276:immunology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy; D009368:Neoplasm Transplantation; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D012513:Sarcoma, Experimental / Q000188:drug therapy / Q000276:immunology / Q000628:therapy; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014750:Vincristine / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D014750:Vincristine; D003520:Cyclophosphamide; D011241:Prednisone